Medicines For Europe And Czech Pharma Body Demand Access Reforms
Proposals Chime With Medicines For Europe’s Longstanding Positions On Pricing And Investment
Executive Summary
Medicines For Europe and Czech association CAFF demand EU and national reforms to help drug makers ensure supply and patient access, particularly in Central and Eastern Europe.
You may also be interested in...
EU Drug Supply In Jeopardy Without Energy Support, Warns Industry Group
Industry body Medicines for Europe is calling for pharmaceutical manufacturers to be excluded from energy restriction policies for winter 2022 in an open letter to EU governance bodies. It warns that inflation and energy costs threaten European drug makers with closures and rationing.
Medicines For Europe Urges Intervention In Inflation Crisis
Medicines for Europe has called for alterations to regulations concerning the off-patent drug sector, which it says will allow the industry to respond more effectively to the region’s dramatic rise in inflation.
EU Pharma Strategy Will Remove Barriers And Bolster Competition
The European Commission’s newly-published Pharmaceutical Strategy features a range of proposals related to generics and biosimilars, including “targeted policies” to improve competition, remove barriers and increase uptake.